Abstract: Objective： To investigate the efficacy and safety of statins combined with bezafibrate in patients with acute coronary syndrome(ACS). Methods： From January 2014 to December 2016， 108 cases of patients with acute coronary syndrome were selected and randomly divided into two groups， each group had 54 cases， the control group was treated with statins， the observation group was treated with statins and bezafibrate. After 3 months of treatment， the clinical efficacy， blood lipid level， inflammatory factor index， adverse reaction rate， liver and kidney function index and myocardial function index were compared between two groups. Results： The total effective rate in the observation group was significantly higher than the control group(P<0.05)； the serum lipid levels in two groups after treatment were significantly improved than before treatment(P<0.05)， total cholesterol(TC)， triglyceride(TG) and low density lipoprotein cholesterol(LDL-C) were decreased， and high density lipoprotein cholesterol(HDL-C) were increased， while after treatment， TC， TG and LDL-C in the observation group were significantly lower than the control group(P<0.05)， HDL-C was significantly higher than the control group(P<0.05)； C reaction protein(CRP)， interleukin 6(IL-6) and other inflammatory factors in two groups after treatment were significantly decreased compared with before treatment(P<0.05)， and the comparison between the two groups after treatment， CRP and IL-6 in the observation group were lower than the control group(P<0.05)； the adverse reactions rate in the observation group and the control group were respectively 5.56% and 9.26%， the difference was not statistically significant(P>0.05)； after treatment， the liver and renal function indexes and myocardial function indexes in the two groups did not change significantly(P>0.05). Conclusion： In the clinical treatment of patients with acute coronary syndrome， the combination of statins and bezafibrate has significant lipid-lowering efficacy， and its safety is reliable.